KR102806328B1 - 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질 - Google Patents

보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질 Download PDF

Info

Publication number
KR102806328B1
KR102806328B1 KR1020207002889A KR20207002889A KR102806328B1 KR 102806328 B1 KR102806328 B1 KR 102806328B1 KR 1020207002889 A KR1020207002889 A KR 1020207002889A KR 20207002889 A KR20207002889 A KR 20207002889A KR 102806328 B1 KR102806328 B1 KR 102806328B1
Authority
KR
South Korea
Prior art keywords
ser
gly
ala
val
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207002889A
Other languages
English (en)
Korean (ko)
Other versions
KR20200026264A (ko
Inventor
브리짓 푸퍼
줄리안 챈들러
니미쉬 게라
더글라스 엘. 쉐리단
시다스 진달
폴 피. 탐부리니
Original Assignee
알렉시온 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렉시온 파마슈티칼스, 인코포레이티드 filed Critical 알렉시온 파마슈티칼스, 인코포레이티드
Priority to KR1020257014994A priority Critical patent/KR20250068795A/ko
Publication of KR20200026264A publication Critical patent/KR20200026264A/ko
Application granted granted Critical
Publication of KR102806328B1 publication Critical patent/KR102806328B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020207002889A 2017-07-11 2018-07-11 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질 Active KR102806328B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257014994A KR20250068795A (ko) 2017-07-11 2018-07-11 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531215P 2017-07-11 2017-07-11
US62/531,215 2017-07-11
PCT/US2018/041661 WO2019014360A1 (en) 2017-07-11 2018-07-11 POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257014994A Division KR20250068795A (ko) 2017-07-11 2018-07-11 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질

Publications (2)

Publication Number Publication Date
KR20200026264A KR20200026264A (ko) 2020-03-10
KR102806328B1 true KR102806328B1 (ko) 2025-05-14

Family

ID=63036501

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207002889A Active KR102806328B1 (ko) 2017-07-11 2018-07-11 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질
KR1020257014994A Pending KR20250068795A (ko) 2017-07-11 2018-07-11 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질
KR1020257021037A Pending KR20250099285A (ko) 2017-07-11 2018-07-11 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257014994A Pending KR20250068795A (ko) 2017-07-11 2018-07-11 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질
KR1020257021037A Pending KR20250099285A (ko) 2017-07-11 2018-07-11 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질

Country Status (12)

Country Link
US (3) US11498960B2 (https=)
EP (1) EP3625265A1 (https=)
JP (3) JP7684803B2 (https=)
KR (3) KR102806328B1 (https=)
CN (3) CN111201246B (https=)
AU (3) AU2018301412B2 (https=)
BR (1) BR112019028269A2 (https=)
CA (1) CA3067247A1 (https=)
CO (1) CO2020000369A2 (https=)
IL (3) IL307197B2 (https=)
MX (2) MX2024005945A (https=)
WO (1) WO2019014360A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102806328B1 (ko) 2017-07-11 2025-05-14 알렉시온 파마슈티칼스, 인코포레이티드 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질
US20210388070A1 (en) * 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
EP3956344A1 (en) * 2019-04-16 2022-02-23 University of Washington Amantadine binding protein
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
BR112022010742A2 (pt) 2019-12-26 2022-08-16 Eisai R&D Man Co Ltd Composição farmacêutica contendo ácido ribonucleico de fita dupla que inibe a expressão de c5 complementar
JP7343618B2 (ja) 2020-01-17 2023-09-12 オリンパス株式会社 発光装置、および駆動装置
EP4135837A1 (en) 2020-04-16 2023-02-22 Assistance Publique, Hopitaux De Paris Methods for treating a complement mediated disorder caused by viruses
IL301713A (en) * 2020-10-05 2023-05-01 Alexion Pharma Inc Methods for treating dermatomyositis
CN120018862A (zh) * 2022-08-31 2025-05-16 阿雷克森制药公司 用于治疗镰状细胞病的融合多肽的剂量和施用
CN116731149B (zh) * 2023-06-07 2024-02-27 华中农业大学 草鱼补体活化分子碳末端肽C5a-CP及应用
CN119241699B (zh) * 2024-09-24 2025-11-28 广州康盛生物科技股份有限公司 一种抗人补体c5的单域抗体及其应用
CN121518561A (zh) * 2025-12-24 2026-02-13 北京林业大学 一种PagRAP2.3蛋白点突变及其在植物愈伤再生中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150064182A1 (en) * 2002-11-08 2015-03-05 Ablynx N.V. Stabilized single domain antibodies

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7083784B2 (en) * 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
AU2012254935B2 (en) * 2004-02-12 2014-05-29 Archemix Llc Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders
TW200607523A (en) * 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN100368022C (zh) 2005-09-20 2008-02-13 中国人民解放军第二军医大学 双重靶向抗肝纤维化药物载体拟糖蛋白纳米粒及其制法
US7807409B2 (en) * 2005-10-21 2010-10-05 Roche Palo Alto Llc Method for the recombinant expression of a polypeptide
SG10201804008UA (en) 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
DK2262831T3 (en) 2008-03-03 2015-04-27 Novelmed Therapeutics Inc ANTI-Properdin ANTIBODIES
PY09026846A (es) * 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
CA2766565A1 (en) * 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP2531523A1 (en) * 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
CA2811221C (en) 2010-03-10 2018-01-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
CN103003296A (zh) 2010-07-09 2013-03-27 阿菲博迪公司 多肽
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
KR20140064768A (ko) 2011-07-01 2014-05-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-프로퍼딘 항체 및 그의 용도
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
WO2013102123A2 (en) 2011-12-28 2013-07-04 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
EP3511339B1 (en) 2012-02-20 2025-04-09 IPC Research, LLC Polypeptides binding to human complement c5
CA2887050A1 (en) 2012-10-04 2014-04-10 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
BR112016003142A2 (pt) 2013-08-28 2017-10-17 Swedish Orphan Biovitrum Ab Publ ligação de polipeptídeos estáveis ao c5 do complemento humano
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
MX2019008827A (es) 2017-01-30 2019-09-26 Alexion Pharma Inc Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
KR102806328B1 (ko) 2017-07-11 2025-05-14 알렉시온 파마슈티칼스, 인코포레이티드 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150064182A1 (en) * 2002-11-08 2015-03-05 Ablynx N.V. Stabilized single domain antibodies

Also Published As

Publication number Publication date
JP7684803B2 (ja) 2025-05-28
RU2020102910A3 (https=) 2021-12-02
KR20200026264A (ko) 2020-03-10
MX2024005945A (es) 2024-06-11
US20250163138A1 (en) 2025-05-22
RU2020102910A (ru) 2021-08-11
CN111201246A (zh) 2020-05-26
AU2018301412A1 (en) 2020-01-30
IL324119A (en) 2025-12-01
US20230235033A1 (en) 2023-07-27
MX2024005946A (es) 2024-06-11
US11498960B2 (en) 2022-11-15
JP2023120208A (ja) 2023-08-29
IL271920A (en) 2020-02-27
JP2020532285A (ja) 2020-11-12
CN117327188A (zh) 2024-01-02
KR20250068795A (ko) 2025-05-16
CO2020000369A2 (es) 2020-01-31
JP2025118590A (ja) 2025-08-13
AU2018301412B2 (en) 2025-08-07
IL271920B2 (en) 2024-03-01
WO2019014360A1 (en) 2019-01-17
US12221473B2 (en) 2025-02-11
WO2019014360A8 (en) 2019-02-21
IL307197A (en) 2023-11-01
IL307197B2 (en) 2026-03-01
BR112019028269A2 (pt) 2020-07-14
AU2018301412A9 (en) 2025-08-07
IL271920B1 (en) 2023-11-01
CA3067247A1 (en) 2019-01-17
EP3625265A1 (en) 2020-03-25
KR20250099285A (ko) 2025-07-01
AU2025200303A1 (en) 2025-02-13
IL307197B1 (en) 2025-11-01
CN117327187A (zh) 2024-01-02
US20200399351A1 (en) 2020-12-24
AU2025200313A1 (en) 2025-02-13
CN111201246B (zh) 2023-10-27

Similar Documents

Publication Publication Date Title
US12221473B2 (en) Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
TWI679211B (zh) 抗ｉｌ－３３抗體和彼之組成物、方法及用途
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
JP2026053563A (ja) 補体関連疾患のための融合タンパク質構築物
KR102709785B1 (ko) Ｉｌ－５ 항체, 이의 항원 결합 단편 및 이의 의학적 적용
CA3225629A1 (en) Novel anti-masp-2 antibodies
RU2794359C2 (ru) Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния
HK40106013A (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
HK40106012A (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
HK40027205B (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
WO2024108529A1 (en) Properdin binding protein and use thereof
RU2824390C2 (ru) Фармацевтическая композиция, содержащая антитело против il-5, и ее применение
HK40027205A (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
BR122025022103A2 (pt) Proteína de fusão, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira isolada, polipeptídeo manipulado, e método de preparação da proteína de fusão
WO2025101747A1 (en) Methods and compositions for treatment of pulmonary hypertension
WO2026008055A1 (zh) 抗kit抗体及其医药用途
HK40127090A (zh) 表皮生长因子受体变体iii抗体
HK40091539A (zh) 新的抗a2ap抗体及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

G17 Pta granted

Free format text: ST27 STATUS EVENT CODE: A-4-4-G10-G17-TAD-PR1102 (AS PROVIDED BY THE NATIONAL OFFICE)

PR1102 Extension of patent period due to registration delay

St.27 status event code: A-4-4-G10-G17-tad-PR1102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 10